Translational Development Acquisition Corp. reported first-quarter 2026 results with net income of $1.33M and diluted EPS of $0.06, down from $1.48M and $0.07, respectively, in the year-ago quarter.
Financial Highlights
- Net income was $1.33M for Q1 2026, down from $1.48M in Q1 2025 (10.2%).
- Diluted EPS was $0.06 for Q1 2026, versus $0.07 in Q1 2025 (14.3%).
Business Highlights
- Business model: Operates as a blank-check company focused on identifying and completing an initial business combination by June 24, 2026.
- Capital deployment: Holds substantial cash equivalents in a Trust Account designated to fund a target acquisition and post-combination operations.
- Operational activity: Primary activities during the quarter were target identification, due diligence and transaction negotiation; the company has no operating revenues to date.
- Liquidity & support: Management expects to rely on Sponsor loans and promissory funding to cover pre-combination operating and diligence costs.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.